Ellagic acid and hydroxyapatite promote angiogenesis marker in bone defect

• Main Authors: Intan Nirwana (Author), Elly Munadziroh (Author), Anita Yuliati (Author), Azalia Izzah Fadhila (Author), Nurliana (Author), Agung Satria Wardhana (Author), Khairul Anuar Shariff (Author), Meircurius Dwi Condro Surboyo (Author)
• Format: Book
• Published: Elsevier, 2022-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2212-4268; 10.1016/j.jobcr.2021.11.008
• Keywords: Angiogenesis; Ellagic acid; Hydroxyapatite; Human & health; Dentistry; RK1-715
• Source: Journal of Oral Biology and Craniofacial Research, Vol 12, Iss 1, Pp 116-120 (2022)

The combination of hydroxyapatite and the herbal extract ellagic acid is expected to accelerate the bone healing process (osteogenesis) due to the extract's anti-inflammatory and antioxidant properties. The osteogenesis process is closely associated with angiogenesis markers, such as fibroblast growth factor 2 (FGF-2), vascular endothelial growth factor (VEGF) and alkali phosphatase (ALP). The objective of this study is to analyse the combination of ellagic acid and hydroxyapatite to promote FGF-2, VEGF and ALP expression as angiogenesis markers in a bone defect model. The research sample comprised 30 male Wistar rats with a defect introduced on the left femur; these were divided into three groups for treatment with ellagic acid and hydroxyapatite, hydroxyapatite and polyethylene glycol (PEG) (control). On days 7 and 14 days after treatment, the Wistar rats were euthanised, and the femoral bone tissue was removed for the immunohistochemical analysis of FGF-2, VEGF and ALP expression. FGF-2 and ALP expression increased in the group treated with ellagic acid and hydroxyapatite on days 7 and 14 post treatment (p < 0.05), and there was an increase in VEGF expression on day 7 post treatment (p < 0.05). The combination of ellagic acid and hydroxyapatite promoted FGF-2, VEGF and ALP expression as angiogenesis markers in the bone defect model.